<p>With exactly 35 days remaining until the August 12 EU PPWR enforcement, the global pharmaceutical and healthcare sectors face a critical audit of their 'Clinical Structural Sovereignty.' For life sciences companies managing sensitive medical inventory, the physical integrity of the secondary packaging is no longer just a regulatory detail; it is a primary barrier to market access. Muge Packaging's 'Clinical Structural Sovereignty' framework identifies 'Molecular Debt'—non-compliant coatings and PFAS-laden films—before they trigger clinical border locks. In the 35-day redline, your packaging is either a sterile asset or a regulatory lien on your entire healthcare network.</p>
Looking for custom packaging for your brand?
